Mining the NCI anticancer drug discovery databases: Genetic function approximation for the QSAR study of anticancer ellipticine analogues

Journal of Chemical Information and Computer Sciences

Volumn 38, Issue 2, 1998, Pages 189-199

  Shi, Leming M ^c   Fan, Yi ^a,d   Myers, Timothy G ^a   O'Connor, Patrick M ^a   Paull, Kenneth D ^a   Friend, Stephen H ^b   Weinstein, John N ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

^d SHIONOGI AND CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ELLIPTICINE DERIVATIVE;

ALGORITHM; ARTICLE; CELL CULTURE; CHEMISTRY; CLUSTER ANALYSIS; DRUG SCREENING; FACTUAL DATABASE; HEALTH CARE ORGANIZATION; HUMAN; REGRESSION ANALYSIS; STRUCTURE ACTIVITY RELATION; UNITED STATES;

ALGORITHMS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CLUSTER ANALYSIS; DATABASES, FACTUAL; DRUG SCREENING ASSAYS, ANTITUMOR; ELLIPTICINES; HUMANS; NATIONAL INSTITUTES OF HEALTH (U.S.); REGRESSION ANALYSIS; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED; UNITED STATES;

EID: 0032015070     PISSN: 00952338     EISSN: None     Source Type: Journal    
DOI: 10.1021/ci970085w     Document Type: Article

References (63)

1. Boyd, M. R. In Cancer: Principles and Practice of Oncology Update; DeVita, V. T.; Hellman, S.; Rosenberg, S. A.; Eds.; J. B. Lippicott: Philadelphia, 1989; Vol. 3.
2. Alley, M. C.; Scudiero, D. A.; Monks, A.; Hursey, M. L.; Czerwinski, M. J.; Fine, D. L.; Abbott, B. J.; Mayo, J. G.; Shoemaker, R. H.; Boyd, M. R. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res. 1988, 48, 589-601.
3. Monks, A.; Scudiero, D. A.; Shoemaker, R. H.; Paull, K. D.; Vistica, D.; Hose, C.; Langley, J.; Cronise, P.; Vaigro-Wolff, A.; Gray-Goodrich, M.; Campell, H.; Mayo, J.; Boyd, M. R. Feasibility of a high-flux anticancer screen using a diverse panel of cultured human tumor lines. J. Natl. Cancer Inst. 1991, 83, 757-766.
4. Boyd, M. R.; Paull, K. D. Some practical considerations and applications of the National Cancer Institute in vitro anticancer drug discovery screen. Drug Devel. Res. 1995, 34, 91-109.
5. Boyd, M. R. In Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval; Teicher, B. A., Ed.; Humana: Totowa, NJ, 1997.
6. Paull, K. D.; Shoemaker, R. H.; Hodes, L.; Monks, A.; Scudiero, D. A.; Rubinstein, L.; Plowman, J.; Boyd, M. R. Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J. Natl. Cancer Inst. 1989, 81, 1088-1092.
7. Weinstein, J. N.; Kohn, K. W.; Grever, M. R.; Viswanadhan, V. N.; Rubinstein, L. V.; Monks, A. P.; Scudiero,D. A.; Welch, L.; Koutsoukos, A. D.; Chiausa, A. J.; Paull, K. D. Neural computing in cancer drug development: Predicting mechanism of action. Science 1992, 258, 447-451.
8. Weinstein, J. N.; Myers, T. G.; O'Connor, P. M.; Friend, S. H.; Fornace, A. J., Jr.; Kohn, K. W.; Fojo, T.; Bates, S. E.; Rubinstein, L. V.; Anderson, N. L.; Buolamwini, J. K.; van Osdol, W. W.; Monks, A. P.; Scudiero, D. A.; Sausville, E. A.; Zaharevitz, D. W.; Bunow, B.; Viswanadhan, V. N.; Johnson, G. S.; Wittes, R. E.; Paull, K. D. An information-intensive approach to the molecular pharmacology of cancer. Science 1997, 275, 343-349.
9. Paull, K. D.; Hamel, E.; Malspeis, L. In Cancer Chemotherapeutic Agents; Foye, W. O., Ed.; American Chemical Society: Washington, D. C., 1995.
10. Koo, H.-M.; Monks, A.; Mikheev, A.; Rubinstein, L. V.; Gray-Goodrich, M.; McWilliams, M. J.; Alvord, W. G.; Oie, H. K.; Gazdar, A. F.; Paull, K. D.; Zarbl, H.; Vande Woude, G. F. Enhanced sensitivity to 1-beta-D-arabinofuranosylcytosine and topoisomerase II inhibitors in tumor cell lines harboring activated ras oncogenes. Cancer Res. 1996, 56, 5211-5216.
11. van Osdol, W. W.; Myers, T. G.; Paull, K. D.; Kohn, K. W.; Weinstein, J. N. Use of the Kohonen self-organizing map to study the mechanisms of action of chemotherapeutic agents. J. Natl. Cancer Inst. 1994, 86, 1853-1859.
12. Koutsoukos, A. D.; Rubinstein, L. V.; Faraggi, D.; Simon, R. M.; Kalyandrug, S.; Weinstein, J. N.; Kohn, K. W.; Paull, K. D. Discrimination techniques applied to the NCI in vitro anti-tumour drug screen: predicting biochemical mechanism of action. Stat. Med. 1994, 13, 719-730.
13. Weinstein, J. N.; Myers, T.; Buolamwini, J.; Raghavan, K.; van Osdol, W.; Licht, J.; Viswanadhan, V. N.; Kohn, K. W.; Rubinstein, L. V.; Koutsoukos, A. D.; Monks, A.; Scudiero, D. A.; Anderson, N. L.; Zaharevitz, D.; Chabner, B. A.; Grever, M. R.; Paull, K. D. Predictive statistics and artificial intelligence in the U.S. National Cancer Institute's Drug Discovery Program for Cancer and AIDS. Stem Cells 1994, 12, 13-22.
14. Bates, S. E.; Fojo, A. T.; Weinstein, J. N.; Myers, T. G.; Alvarez, M.; Paull, K. D.; Chabner, B. A. Molecular targets in the National Cancer Institute drug screen. J. Cancer Res. Clin. Oncol. 1995, 121, 495-500.
15. Li, G.; Waltham, M.; Unsworth, E.; Treston, A.; Mushine, J.; Anderson, N. L.; Kohn, K. W.; Weinstein, J. N. Rapid protein identification from two-dimensional polyacrylamide gels by MALDI mass spectrometry. Electrophoresis 1997, 18, 391-402.
16. Myers, T. G.; Waltham, M.; Li, G.; Buolamwini, J. K.; Scudiero, D. A.; Rubinstein, L. V.; Paull, K. D.; Sausville, E. A.; Anderson, N. L.; Weinstein, J. N. A protein expression database for the molecular pharmacology of cancer. Electrophoresis 1997, 18, 647-653.
17. Milne, G. W. A.; Miller, J. A. The NCI Drug Information System. 1. System overview. J. Chem. Inf. Comput. Sci. 1986, 26, 154-159.
18. Milne, G. W. A.; Feldman, A.; Miller, J. A.; Daly, G. P.; Hammel, M. J. The NCI Drug Information System. 2. DIS pre-registery. J. Chem. Inf. Comput. Sci. 1986, 26, 159-168.
19. Milne, G. W. A.; Feldman, A.; Miller, J. A.; Daly, G. P. The NCI Drug Information System. 3. The DIS chemistry module. J. Chem. Inf. Comput. Sci. 1986, 26, 168-179.
20. Milne, G. W. A.; Miller, J. A.; Hoover, J. R. The NCI Drug Information System. 4. Inventory and shipping modules. J. Chem. Inf. Comput. Sci. 1986, 26, 179-185.
21. Klopman, G.; Shi, L. M.; Ramu, A. Quantitative structure-activity relationship of multidrug resistance reversal agents. Mol. Pharmacol. 1997, 52, 323-334.
22. Klopman, G. Artificial intelligence approach to structure-activity studies. Computer automated structure evaluation of biological activity of organic molecules. J. Am. Chem. Soc. 1984, 106, 7315-7320.
23. Klopman, G. MULTICASE: a hierarchical computer automated structure evaluation program. QSAR 1992, 11, 176-184.
24. Milne, G. W. A.; Nicklaus, M. C.; Driscoll, J. S.; Wang, S.; Zaharevitz, D. National Cancer Institute Drug Information System 3D database. J. Chem. Inf. Comput. Sci. 1994, 34, 1219-1224.
25. Wang, S.; Zaharevitz, D. W.; Sharma, R.; Marquez, V. E.; Lewin, N. E.; Du, L.; Blumberg, P. M.; Milne, G. W. A. The discovery of novel, structurally diverse protein kinase C agonists through computer 3D-database search. Molecular modeling studies. J. Med. Chem. 1994, 37, 4479-4489.
26. Wang, S.; Milne, G. W. A.; Yan, X.; Posey, I.; Nicklaus, M. C.; Graham, L.; Rice, W. G. Discovery of novel, non-peptide HIV-1 protease inhibitors by pharmacophore searching. J. Med. Chem. 1996, 39, 2047-2054.
27. Nicklaus, M. C.; Neamati, N.; Hong, H.; Mazumder, A.; Sunder, S.; Chen, J.; Milne, G. W. A.; Pommier, Y. HIV-1 integrase pharmacophore: Discovery of inhibitors through three-dimensional database searching. J. Med. Chem. 1997, 40, 920-929.
28. Hong, H.; Neamati, N.; Wang, S.; Nicklaus, M. C.; Mazumder, A.; Zhao, H.; Burke, T. R.; Pommier, Y.; Milne, G. W. A. Discovery of HIV-1 integrase inhibitors by pharmacophore searching. J. Med. Chem. 1997, 40, 930-936.
29. Myers, T. G.; Weinstein, J. N.; Raghavan, K.; Buolamwini, J.; Anderson, N. L.; O'Connor, P.; Kohn, K. W.; Scudiero, D. A.; Monks, A. P.; Friend, S. An 'information-intensive' strategy for drag discovery in cancer and AIDS: Relating cell cycle factors to patterns of drug activity. Proc. Ann. Meeting Am. Assoc. Cancer Res. 1995, 36, 305.
30. Myers, T. G.; Paull, K. D.; Kohn, K. W.; Fojo, A. T.; Bates, S.; Weinstein, J. N. Molecular determinants of in vitro cytotoxicity in the NCI drag screen. Proc. Ann. Meeting Am. Assoc. Cancer Res. 1996, 37, 299.
31. Harris, C. C. p53 tumor suppressor gene: from the basic research laboratory to the clinic - an abridged historical perspective. Carcinogenesis 1996, 17, 1187-1198.
32. Hollstein, M.; Sidransky, D.; Vogelstein, B.; Harris, C. C. p53 mutations in human cancers. Science 1991, 253, 49-53.
33. O'Connor, P. M.; Jackman, J.; Bae, I.; Myers, T. G.; Fan, S.; Mutoh, M.; Scudiero, D. A.; Monks, A.; Sausville, E. A.; Weinstein, J. N.; Friend, S.; Fornance, J., A. J.; Kohn, K. W. Characterization of the p53-tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res. 1997, 57, 4285-4300.
34. Benhattar, J.; Cerottini, J. P.; Saraga, E.; Metthez, G.; Givel, J. C. p53 mutations as a possible predictor of response to chemotherapy in metastatic colorectal carcinomas. Int. J. Cancer (Pred. Oncol.) 1996, 69, 190-2.
35. Shi, L. M.; Myers, T. G.; Fan, Y.; O'Conner, P. M.; Paull, K. D.; Friend, S. H.; Weinstein, J. N. Mining the NCI anticancer drug discovery database: cluster analysis of ellipticine analogs with p53-inverse and CNS-selective patterns of activity. Mol. Pharmacol. in press.
36. Goodwin, S.; Smith, A. F.; Horning, E. C. Alkaloids of Ochrosia elliptica Labill. J. Am. Chem. Soc. 1959, 81, 1903-1908.
37. Dalton, L. K.; Demerac, S.; Elmes, B. C.; Lorder, J. W.; Swan, J. M.; Teitel, T. Synthesis of the tumor-inhibitory alkaloids, ellipticine, 9-methoxyellipticine, and related pyrido[4,3-b]carbazoles. Aust. J. Chem. 1967, 20, 2715-2727.
38. Gribble, G. W. In The Alkaloids: Chemistry and Pharmacology; Brossi, A., Ed.; Academic: San Diego, 1990; Vol. 39.
39. Acton, E. M.; Narayanan, V. L.; Risbood, P. A.; Shoemaker, R. H.; Vistica, D. T.; Boyd, M. R. Anticancer specificity of some ellipticinium salts against human tumors in vitro. J. Med. Chem. 1994, 37, 2185-2189.
40. Anderson, W. K.; Gopalsamy, A.; Reddy, P. S. Design, synthesis and study of 9-substituted ellipticine and 2-methylellipticinium analogues as potential CNS-selective antitumor agents. J. Med. Chem. 1994, 37, 1955-1963.
41. Jurayi, J.; Haugwitz, D.; Varma, R. K.; Paull, K. D.; Barrett, J. F.; Cushman, M. Design and synthesis ellipticinium salts and 1,2-dihydroellipticines with high selectivities against human CNS cancers in vitro. J. Med. Chem. 1994, 37, 2190-2197.
42. Devraj, R.; Jurayj, J.; Fernanden, J. A.; Barrett, J. F.; Cushman, M. Synthesis of a series of cytotoxic 2-acyl-1,2-dihydroellipticines which inhibit topoisomerase II. Anti-Cancer Drug Design 1996, 11, 311-324.
43. Devraj, R.; Barrett, J. F.; Fernandez, J. A.; Katzenellenbogen, J. A.; Cushman, M. Design, synthesis, and biological evaluation of ellipticine-estradiol conjugates. J. Med. Chem. 1996, 39, 3367-3374.
44. Shimamoto, T.; Imajo, S.; Honda, T.; Yoshimura, S.; Ishiguro, M. Structure-activity relationship study on N-glycosyl moieties through model building of DNA and ellipticine N-glycoside complex. Bioorg. Med. Chem. Lett. 1996, 6, 1331-1334.
45. Vistica, D. T.; Kenney, S.; Hursey, M. L.; Boyd, M. R. Cellular uptake as a determinant of cytotoxicity of quaternized ellipticines to human brain tumor cells. Biochem. Biophys. Res. Commun. 1994, 200, 1762-1768.
46. Kenney, S.; Vistica, D. T.; Linden, H.; Boyd, M. R. Uptake and cytotoxicity of 9-methoxy-N2-methylellipticinium acetate in human brain and non-brain tumor cell lines. Biochem. Pharmacol. 1995, 49, 23-32.
47. Kohn, K. W.; Waring, M. J.; Glaubiger, D.; Friedman, C. A. Intercalative binding of ellipticine to DNA. Cancer Res. 1975, 35, 71-76.
48. Sainsbury, M. In The Chemistry of Antitumor Agents; Wilman, D., Ed.; Chapman and Hall: New York, 1990.
49. Froelich, A. S.; Patchan, M. W.; Osheroff, N.; Thompson, R. B. Topoisomerase II binds to ellipticine in the absence or presence of DNA. Characterization of enzyme-drug interactions by fluorescence spectroscopy. J. Biol. Chem. 1995, 270, 14998-15004.
50. Rappe, A. K.; Casewit, C. J.; Colwell, K. S.; Goddard, W. A.; Skiff, W. M. UFF, a full periodic table force field for molecular mechanics and molecular dynamics simulations. J. Am. Chem. Soc. 1992, 114, 10024-10035.
51. Rappe, A. K.; Goddard, W. A. J. Phys. Chem. 1991, 95, 3358.
52. Hansch, C.; Leo, A.; Hoekman, D. Exploring QSAR, vol. 1. Fundamentals and Applications in Chemistry and Biology; vol. 2. Hydrophobic, Electronic, and Steric Constants; American Chemical Society: Washington. D.C., 1995.
53. Chemometric Methods in Molecular Design; van de Waterbeemd, H., Ed.; VCH: Weinheim, 1995; Vol. 2.
54. Advanced Computer-Assisted Techniques in Drug Discovery; van de Waterbeemd, H., Ed.; VCH: Weinheim, 1995; Vol. 3.
55. Structure-Property Correlations in Drug Research; van de Waterbeemd, H., Ed.; Academic and R. G. Landes: San Diego, 1996.
56. Rogers, D.; Hopfinger, A. J. Application of genetic function approximation to quantitative structure-activity relationships and quantitative structure-property relationships. J. Chem. Inf. Comput. Sci. 1994, 34, 854-866.
57. Rogers, D. In Genetic Algorithms in Molecular Modeling; Devillers, J., Ed.; Academic: London, 1996.
58. Friedman, J. H. Multivariate Adaptive Regression Splines, Technical Report No. 102, Nov/Rev.1990 Aug; Laboratory of Computational Statistics, Department of Statistics, Stanford University: Standford, CA, 1988.
59. Friedman, J. H. Multivariate adaptive regression splines (with discussion). Ann. Stat. 1991, 19, 1-141.
60. Holland, J. Adaptation in Artificial and Natural Systems; University of Michigan: Ann Arbor, MI, 1975.
61. Shi, L. M.; Myers, T. G.; Fan, Y.; Weinstein, J. N. Fifth Conference on Current Trends in Computational Chemistry (CCTCC), Vicksburg, Mississippi, 1996; pp 131-135.
62. Shi, L. M.; Fan, Y.; Myers, T. G.; Weinstein, J. N. Proceedings of the 1997 International Conference on Neural Networks (ICNN'97), Houston, Texas, 1997; pp 2490-2493.
63. StatSci S.-PLUS Reference Manual; MathSoft: Seattle, WA, 1993.